Experimentally induced phenylbutazone toxicosis in ponies: description of the syndrome and its prevention with synthetic prostaglandin E2.

The research article discusses an experiment conducted on ponies to understand the effects of phenylbutazone (PBZ) toxicosis, and how a synthetic prostaglandin E2 can prevent its severe symptoms. The study reveals that mucosal atrophy is a chief symptom of PBZ toxicosis, and prostaglandin synthesis inhibition plays a significant part in its genesis.

Research Design and Process

• The experiment was initiated by inducing phenylbutazone (PBZ) toxicosis in 9 ponies. The goal was to examine and describe the clinical and pathological changes that occur with this syndrome.
• A group of another six ponies were treated with both PBZ and a synthetic prostaglandin E2. The objective of this treatment combination was to determine the role of prostaglandins in the development of PBZ toxicosis.

Findings from the PBZ Only Treatment Group

• Ponies only given PBZ displayed several adverse health symptoms, including depression of the Central Nervous System (CNS), reduced appetite, weight loss, diarrhea, and bluish discoloration (cyanosis) of mucous membranes.
• They also developed oral ulcers, and their total serum protein concentration decreased progressively for the 10-day treatment period.
• Furthermore, they experienced significant mucosal atrophy, focal erosions, and ulcers in their alimentary tract.

Findings from the PBZ with Prostaglandin E2 Treatment Group

• On the other hand, ponies given both PBZ and prostaglandin E2 remained clinically healthy and did not develop hypoproteinemia – a condition signified by unusually low levels of proteins in the blood – or mucosal atrophy.
• While few erosions were noted, ulcers were not observed in these ponies.

Conclusions from the Study

• The researchers concluded that mucosal atrophy is a distinctive symptom of PBZ toxicosis.
• The study also suggests that the process of inhibiting prostaglandin synthesis, which can be prevented by introducing synthetic prostaglandin E2, plays an essential role in the evolution of this syndrome.